Single Nucleus RNA Sequencing for Brain Tumors

The cell stands as the fundamental functional unit of life. Single-cell sequencing is recognized as a potent technical methodology to unravel diverse life phenomena and explore various biological mechanisms. While single-cell RNA sequencing (scRNA-seq) at times falls short in delivering a comprehensive analysis of neural cell types, single-nucleus RNA sequencing (snRNA-seq) has significantly addressed this limitation. Alfa Cytology provides expertly designed single-nucleus RNA sequencing tailored specifically for brain tumor research.

Single Nucleus RNA Sequencing in Brain Tumors

Single-nucleus RNA sequencing (snRNA-seq) stands out as an advanced method for examining the gene expression profiles of individual cell nuclei. With no need for cell isolation, snRNA-seq proves particularly valuable in the study of brain tumor tissues, where enzymatic cell isolation could damage neurons and it is difficult to obtain fresh human brain tissues. Furthermore, recent studies have revealed that snRNA-seq identifies more neurons compared to single-cell RNA sequencing (scRNA-seq), indicating the great potential of snRNA-seq in elucidating the cellular and molecular landscape of brain tumors.

Fig.1 snRNA-seq identifies gene expression programs driving cell states in IDH-mutant gliomas. (Blanco-Carmona E., et al., 2023)

Alfa Cytology provides specialized snRNA-seq services that encompass nuclei isolation from brain tumor tissues and high-throughput sequencing analysis of the transcriptome at the individual nucleus level. By scrutinizing the gene expression profiles of individual nuclei, we assist in revealing the heterogeneity present among brain tumor cells. Our extensive expertise supports the reliability and credibility of snRNA-seq research in brain tumors. Moreover, we have devised tailored protocols for the thorough analysis of snRNA-seq data.

Workflow of Single Nucleus RNA Sequencing

In the process of isolating single-cell nuclei, we focus on minimizing enzymatic digestion and reducing the generation of pseudocellular taxa induced by mechanical stress. In terms of data analysis, our snRNA-seq methodology allows us to capture information from intron regions and intergenic regions, enhancing the precision of cell type identification and providing extensive genetic information on brain tumor cells.

Sample Requirement

• Tissue amount ≥ 1 g.
• Sample processing. Tissue is snap-frozen in liquid nitrogen and stored at -80 °C.
• Quality requirements. No degradation of tissue RNA, RIN ≥ 7.

Application of Single Nucleus RNA Sequencing for Brain Tumors

Reveal the activation state of neurons during brain tumor progression.

Acquire a comprehensive cellular profile of brain tumor cells.

Assist researchers in cataloging various brain tumors.

Advantages of Our Single Nucleus RNA Sequencing

• Broad Sample Types. The sample variety is significantly broadened and the process of single nucleus RNA sequencing is greatly streamlined and stabilized. The snRNA-seq service we provide is compatible with frozen tissues, guaranteeing the generation of high-quality data and consistent results.
• Accurate single nucleus RNA determination. There are no artificial biases introduced in our snRNA-seq. The sequencing results faithfully reflect the transcriptional patterns of cells at the sampling time, providing accurate insights into the transcriptional status of the cells.
• High resolution sequencing. We can mine data in combination with pathological features and offer high-resolution single nucleus RNA sequencing tailored to brain tumor research.

Contact Us

With its consistent and dependable outcomes, snRNA-seq technology has emerged as the potent method for brain tumor research. Alfa Cytology is committed to linking cell phenotypes, genotypes and transcriptional patterns of cell nuclei to enhance the understanding of the intricacies within the brain tumors. By comprehending these mechanisms and employing diverse analytical approaches, we aim to achieve profound insights into the realm of brain tumors. For further details, please feel free to contact us.

Reference

1. Blanco-Carmona E.; et al. (2023). Tumor heterogeneity and tumor-microglia interactions in primary and recurrent IDH1-mutant gliomas[J]. Cell reports. Medicine. 4(11), 101249.